Cytek Biosciences shows a bullish momentum-continuation setup and an attractive PEG ratio, but a sub-floor quality score, thin free-cash-flow margins, a history of large negative earnings surprises, and weak asymmetry keep the engine's stance at exit.
Thesis pillars
- Thin Fcf Margin Risk→Stable
- Momentum Continuation Setup→Stable
- Peg Valuation Cheapness→Stable
- +2 more pillars — see the Why tab for full reasoning
Cytek Biosciences, Inc. (CTKB) Stock Analysis
Range Bound setup · Inst Constrain edge
Healthcare · Medical Devices
Sell if holding. Engine safety override at $4.39: Quality below floor (3.5 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.4/10. Specifically: Below-average business quality; Below long-term trend.
Cytek Biosciences develops Full Spectrum Profiling cell-analysis instruments — the Cytek Aurora, Northern Lights, and Aurora Evo systems — plus the Amnis and Guava flow cytometry lines acquired in February 2023, selling to pharmaceutical, biopharma, academic, and contract... Read more
Sell if holding. Engine safety override at $4.39: Quality below floor (3.5 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.4/10. Specifically: Below-average business quality; Below long-term trend. Chart setup: RSI 59 mid-range, Bollinger mid-band. Score 5.4/10, moderate confidence.
Passes 7/9 gates (positive momentum, clean insider activity, no SEC red flags, news events none recent, earnings proximity 30d clear, semi cycle peak clear, materials cycle peak clear). Fails on favorable risk/reward ratio. Suitability: aggressive.
About Cytek Biosciences, Inc.
About Cytek Biosciences, Inc.
Cytek Biosciences generated $201.5 million in revenue for fiscal 2025, roughly flat versus $200.5 million in fiscal 2024, while swinging to a $66.5 million net loss from a $6.0 million loss the prior year. The company's Full Spectrum Profiling technology powers its Cytek Aurora, Northern Lights, and Aurora Evo cell analyzers, sold alongside the Amnis and Guava flow cytometry lines it acquired in February 2023, to pharmaceutical companies, biopharma firms, academic research centers, and contract research organizations worldwide.
Cytek earns revenue primarily from instrument sales followed by recurring reagent and consumables pull-through as its installed base grows, supported by a commercial team of more than 270 people and an R&D group exceeding 150 employees among its roughly 700 total staff. The FSP platform's 50-color, single-tube multiplexing is designed to differentiate it from conventional and mass cytometry, and the company is pursuing clinical-use registrations for its Northern Lights-CLC system, already approved in the European Union and China, ahead of a planned U.S. regulatory filing. Cytek ended 2025 with $261.5 million in cash, restricted cash, and short-term investments, down from $277.9 million a year earlier as it funded continued R&D and commercial expansion.
Show full overview
Cytek discloses it is highly dependent on a limited number of product offerings, with the Cytek Aurora, Northern Lights, Aurora CS, and Aurora Evo systems together accounting for a substantial portion of revenue, leaving results sensitive to the roughly six-month-or-longer sales cycle for capital equipment. Certain lasers and semiconductors used in its optical and fluidic subassemblies come from sole or single-source suppliers, including Coherent NA under a supply agreement most recently amended in August 2025 to extend its term and add Cytek's Singapore subsidiary as a party, concentrating a key input in one vendor relationship the company could not immediately replace if disrupted.
See also: Healthcare · Medical Devices
From Cytek Biosciences, Inc.'s most recent 10-K filing, extracted July 6, 2026.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
3 floor-breakers
No near-term catalyst priced in. Thesis progression will come from fundamentals grinding, not event reaction.static
Unprofitable operations — net margin -36.2%. Quality floor flags this regardless of sector context.static
Technicals below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $4.39: Quality below floor (3.5 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.4/10. Specifically: Below-average business quality; Below long-term trend. Chart setup: RSI 59 mid-range, Bollinger mid-band. Prior stop was $4.08. Score 5.4/10, moderate confidence.
Take-profit target: $4.83 (+10.0% upside). Prior stop was $4.08. Stop-loss: $4.08.
Quality below floor (3.5 < 4.0); Value-trap signals (2/5): Margin compression (op margin -5311.1%), Negative free cash flow.
Cytek Biosciences, Inc. trades at a P/E of N/A (forward 24.3). TrendMatrix value score: 7.6/10. Verdict: Sell.
10 analysts cover CTKB with a consensus score of 4.0/5. Average price target: $6.
What does Cytek Biosciences, Inc. do?Cytek Biosciences develops Full Spectrum Profiling cell-analysis instruments — the Cytek Aurora, Northern Lights, and...
Cytek Biosciences develops Full Spectrum Profiling cell-analysis instruments — the Cytek Aurora, Northern Lights, and Aurora Evo systems — plus the Amnis and Guava flow cytometry lines acquired in February 2023, selling to pharmaceutical, biopharma, academic, and contract research customers worldwide. The company generated $201.5 million in revenue in fiscal 2025, roughly flat with $200.5 million in 2024, while net losses widened to $66.5 million from $6.0 million as it held $261.5 million in cash and short-term investments at year-end.